Profile data is unavailable for this security.
About the company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-2.34m
- Incorporated2015
- Employees6.00
- LocationMustang Bio Inc95 Sawyer Rd, Suite 110WALTHAM 02453United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (302) 531-3150
- Websitehttps://www.mustangbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bullfrog AI Holdings Inc | 116.67k | -6.76m | 5.59m | 9.00 | -- | 2.63 | -- | 47.94 | -0.6936 | -0.6936 | 0.0119 | 0.1866 | 0.0319 | -- | -- | 12,963.33 | -184.34 | -- | -233.50 | -- | 18.76 | -- | -5,770.66 | -- | -- | -- | 0.0278 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 5.68m | 37.00 | -- | 0.17 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 5.76m | 1.00 | -- | 2.03 | -- | 959.69 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 5.76m | 0.00 | -- | 2.89 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 6.27m | 4.00 | -- | 1.43 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.40m | 4.00 | -- | 0.8445 | -- | 1,065.87 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.42m | 1.00 | -- | 0.2501 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 6.45m | 22.00 | -- | 0.2764 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.49m | 6.00 | -- | 0.6646 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 6.60m | 2.00 | -- | 0.1242 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 6.93m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 7.13m | 37.00 | -- | 0.3154 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.27m | 1.00 | -- | 0.7042 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Aclarion Inc | 67.48k | -7.39m | 7.39m | 6.00 | -- | 0.1207 | -- | 109.56 | -1,687.50 | -1,687.50 | 0.1948 | 21.46 | 0.0082 | -- | 2.76 | 11,246.67 | -89.50 | -- | -97.72 | -- | -7.85 | -- | -10,868.49 | -- | -- | -25,428.22 | 0.00 | -- | -39.36 | -- | -43.60 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.43m | 12.00 | -- | 0.3095 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Mustang Bio Inc's reporting currency: US Dollar USD
6.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kestra Advisory Services LLCas of 31 Dec 2025 | 111.04k | 1.72% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 84.73k | 1.31% |
| DRW Securities LLCas of 31 Dec 2025 | 73.94k | 1.15% |
| Geode Capital Management LLCas of 31 Dec 2025 | 32.29k | 0.50% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 32.12k | 0.50% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 25.70k | 0.40% |
| XTX Markets LLCas of 30 Sep 2025 | 18.78k | 0.29% |
| Jane Street Capital LLCas of 31 Dec 2025 | 14.13k | 0.22% |
| CFO4Life Group LLCas of 31 Dec 2025 | 12.96k | 0.20% |
| GSA Capital Partners LLPas of 31 Dec 2025 | 12.83k | 0.20% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
